Literature DB >> 32479949

Hyaluronic acid induction on breast cancer stem cells unfolds subtype specific variations in stemness and epithelial-to-mesenchymal transition.

Heena Jariyal1, Chanchal Gupta2, Akshay Srivastava3.   

Abstract

The reoccurrence of breast cancer is a major concern due to presence of cancer stem cells (CSCs). Considering the key role of hyaluronic acid (HA) in modulating the inflammation and cellular migration in cancer, the response of high molecular weight (HMW) and low molecular weight (LMW) HA towards various subtypes of breast cancer and breast cancer stem cells remain elusive. The aim of this study is to determine the effect of exogenous HMW-HA and LMW-HA on stemness of CSCs and epithelial-to-mesenchymal transition which may help in designing HA based therapeutic strategies. LMW-HA induces EMT in MCF-7 more prominently as compared to MDA-MB-231. However, HMW-HA did not show significant changes in the expression of EMT genes. Surprisingly, both HMW-HA and LMW-HA have shown to decrease the expression of EpCAM in MCF-7 cells and decrease the expression of CD44 in MDAMB-231 cells. HA has maintained the native stem cells phenotype of bCSCs isolated from MCF-7 only. The bCSCs isolated form MDAMB-231 showed a decrease in CD44. Luminal subtype has shown to follow Wnt/β-catenin whereas in the basal subtype localization of CD44 from surface to cytosol was observed in response to HA. Our study has demonstrated that bCSCs in luminal and basal cells follow differential intracellular signaling mechanisms in response to HA. This study could significantly influence the therapeutics involving HA in breast cancer.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cancer stem cells; EpCAM; Hyaluronic acid; β-Catenin

Mesh:

Substances:

Year:  2020        PMID: 32479949     DOI: 10.1016/j.ijbiomac.2020.05.236

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  7 in total

1.  Mortalin maintains breast cancer stem cells stemness via activation of Wnt/GSK3β/β-catenin signaling pathway.

Authors:  Bo Wei; Jia Cao; Jin-Hai Tian; Chuan-Yang Yu; Qi Huang; Jing-Jing Yu; Rong Ma; Jia Wang; Fang Xu; Li-Bin Wang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 2.  Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Authors:  Yunchun Zhao; Xiaoling Zheng; Yongquan Zheng; Yue Chen; Weidong Fei; Fengmei Wang; Caihong Zheng
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

3.  O-linked α2,3 sialylation defines stem cell populations in breast cancer.

Authors:  Melanie R Walker; Hira Lal Goel; Dimpi Mukhopadhyay; Peter Chhoy; Emmet R Karner; Jennifer L Clark; Haibo Liu; Rui Li; Julie Lihua Zhu; Shuhui Chen; Lara K Mahal; Barbara A Bensing; Arthur M Mercurio
Journal:  Sci Adv       Date:  2022-01-07       Impact factor: 14.136

4.  Identification of potential immunotherapy biomarkers for breast cancer by bioinformatics analysis.

Authors:  Yao Song; Meiling Lu; Lijin Feng; Qian Chen; Hua Huang; Qing Lin
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840

5.  Microarray analysis of breast cancer gene expression profiling in response to 2-deoxyglucose, metformin, and glucose starvation.

Authors:  Rita Aoun; Christopher El Hadi; Roula Tahtouh; Rita El Habre; George Hilal
Journal:  Cancer Cell Int       Date:  2022-03-19       Impact factor: 5.722

6.  Modulation of Cell-Cycle Progression by Hydrogen Peroxide-Mediated Cross-Linking and Degradation of Cell-Adhesive Hydrogels.

Authors:  Wildan Mubarok; Kelum Chamara Manoj Lakmal Elvitigala; Masaki Nakahata; Masaru Kojima; Shinji Sakai
Journal:  Cells       Date:  2022-03-03       Impact factor: 6.600

Review 7.  Mesenchymal stem cells: ideal seeds for treating diseases.

Authors:  Guanwen Gao; Chenyang Fan; Weiquan Li; Runzhang Liang; Chuzhong Wei; Xiaojie Chen; Yue Yang; Yueyuan Zhong; Yingqi Shao; Yi Kong; Zesong Li; Xiao Zhu
Journal:  Hum Cell       Date:  2021-07-16       Impact factor: 4.374

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.